GYRE THERAPEUTICS, INC.
GYRE THERAPEUTICS, INC. (GYRE): 10 pipeline candidates · 3 upcoming catalysts · ~6 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
5.8 months
D/E 0.25 · 0% dilution
Lead: Approved
10 candidates
3 upcoming, next in ~767d
0 buys · 12 sells (180d)
A transparent, data-derived signal for GYRE THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$557.3M
Cash
$37.5M
Quarterly Burn
$31.9M
Runway
5.8 mo
Revenue
$22.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| avatrombopag | Approved |
| contiva | Approved |
| etorel | Approved |
| etuary | Phase 3 |
| f230 | Preclinical |
| f351 | Preclinical |
| f528 | Preclinical |
| f573 | Phase 2 |
| hydronidone | Phase 3 |
| nintedanib | Approved |
Upcoming Catalysts (3)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$29.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,968,408 | $13.7M |
| blackrock, inc. | 758,630 | $5.3M |
| geode capital management, llc | 431,414 | $3.0M |
| state street corp | 216,326 | $1.5M |
| charles schwab investment management inc | 165,238 | $1.2M |
| vanguard fiduciary trust co | 137,682 | $960K |
| northern trust corp | 133,841 | $933K |
| goldman sachs group inc | 73,122 | $510K |
| vanguard portfolio management llc | 69,814 | $487K |
| bank of new york mellon corp | 43,144 | $301K |
Showing top 10 of 55 institutional holders of GYRE THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GYRE THERAPEUTICS, INC.'s pipeline?
GYRE THERAPEUTICS, INC. (GYRE) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GYRE THERAPEUTICS, INC.'s lead drug candidate?
GYRE THERAPEUTICS, INC.'s most advanced tracked candidate is avatrombopag (Approved) for Thrombocytopenia (TP) associated with chronic liver disease (CLD) and chronic idiopathic thrombocytopenia (ITP).
What is GYRE THERAPEUTICS, INC.'s next catalyst?
GYRE THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: DOPTELET" — expected July 24, 2028.
What is GYRE THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GYRE THERAPEUTICS, INC. has approximately 5.8 months of cash runway.
What is GYRE THERAPEUTICS, INC.'s market capitalization?
GYRE THERAPEUTICS, INC.'s market capitalization is approximately $557.3M.
Get the full picture on GYRE THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.